Insights on ESG Ratings
NORTHAMPTON, MA / ACCESSWIRE / April 5, 2024 / Julian Kölbel, assistant professor at the University of St. Gallen and a research affiliate at the MIT Sloan School of Management, joins co-host Mandi McReynolds for a discussion on ESG rating agencies. Listen in as they delve into his research on sustainable investing with a focus on ESG ratings, the disagreement between different rating agencies, and how it affects investors and companies.
For more information on Julian's work, check out his research: Aggregate Confusion: The Divergence of ESG Ratings.
Looking for more? Subscribe to the ESG Talk podcast on Apple, Spotify, Google, and YouTube.
View additional multimedia and more ESG storytelling from Workiva on 3blmedia.com.
Contact Info:
Spokesperson: Workiva
Website: https://www.3blmedia.com/profiles/workiva
Email: info@3blmedia.com
SOURCE: Workiva
View the original press release on accesswire.com
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track